Abstract
Purpose:
To evaluate safety and efficacy of High-Intensity Focused Ultrasound (HIFU) Cyclocoagulation for treatment of refractory glaucoma.
Methods:
15 glaucoma patients underwent IOP-lowering treatment with (UC3, EyeTechCare, France) in a prospective manner. All interventions were performed under general anesthesia. Success was defined as an IOP reduction of >20% from baseline.
Results:
Mean age of study population was 42 ± 10.2 years (67% women). Main diagnosis was neovascular glaucoma (n=5), followed by primary open angle glaucoma (n=4) and different forms of secondary glaucoma (n=6). Baseline IOP was 31.6±5.7 mmHg. After HIFU treatment, IOP was 25.2±6.5 mmHg, 22.0±9.4 mmHg, 20.9± 6.3 mmHg, 24.2±11.5 mmHg and 23.3±11.7 mmHg at day 1, week 1, month 1, month 6 and 1 year, respectively. The average IOP reduction from baseline was -29%.<br /> Data from 9 out of 15 patients were available at the 1-year follow-up visit. Among these, 5 (56%) were considered as successful. No serious adverse events were recorded.
Conclusions:
HIFU seems to be an efficient and safe treatment for eyes with refractory glaucoma.